Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The COVID-19 pandemic has motivated researchers all over the world in trying to find effective drugs and therapeutics for treating this disease. To save time, much effort has focused on repurposing drugs known for treating other diseases than COVID-19. To support these drug repurposing efforts, we built the CAS Biomedical Knowledge Graph and identified 1350 small molecules as potentially repurposable drugs that target host proteins and disease processes involved in COVID-19. A computer algorithm-driven drug-ranking method was developed to prioritize those identified small molecules. The top 50 molecules were analyzed according to their molecular functions and included 11 drugs in clinical trials for treating COVID-19 and new candidates that may be of interest for clinical investigation. The CAS Biomedical Knowledge Graph provides researchers an opportunity to accelerate innovation and streamline the investigative process not just for COVID-19 but also in many other diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.jcim.1c00642 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Statins as Antifungal Agents: A Review on Drug Repurposing and Nanotechnology-Driven Delivery Strategies.
Fundam Clin Pharmacol
October 2025
Postgraduate Program in Pharmaceutical Science, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil.
This review highlights the integration of drug repurposing and nanotechnology-driven delivery strategies as innovative approaches to enhance the antifungal activity of statins against mucosal candidiasis, providing a framework for future translational research and clinical application. The rising prevalence of antifungal resistance and virulence factors of Candida albicans underscore the limitations of current therapies. Statins, commonly used as lipid-lowering agents, have emerged as attractive repurposed drug candidates due to their ability to interfere with fungal ergosterol biosynthesis and Ras-mediated signaling pathways.
View Article and Find Full Text PDFCardiovascular Safety of COVID-19 Treatments: A Disproportionality Analysis of Adverse Event Reports from the WHO VigiBase.
Infect Dis Ther
September 2025
School of Biomedical Sciences, The Chinese University of Hong Kong (CUHK), Hong Kong SAR, China.
Introduction: The high mortality of Coronavirus Disease 2019 (COVID-19) highlights the need for safe and effective antiviral treatment. Small molecular antivirals (remdesivir, molnupiravir, nirmatrelvir/ritonavir) and immunomodulators (baricitinib, tocilizumab) have been developed or repurposed to suppress viral replication and ameliorate cytokine storms, respectively. Despite U.
View Article and Find Full Text PDFIntegrative multi-omics identifies S100A8/IGFBP5/CTSK/S100P as dual diagnostic biomarkers and therapeutic targets in Crohn's disease: from computational discovery to preclinical validation.
Int Immunopharmacol
September 2025
Interdisciplinary eye research institute (EYE-X Institute), Bengbu Medical University, Bengbu, Anhui, China; Anhui Provincial Key Laboratory of Immunology in Chronic Diseases, Bengbu Medical University, Anhui, China. Electronic address:
Crohn's disease (CD) is a chronic inflammatory bowel condition that significantly impairs patients' quality of life. With no cure currently available, the need to discover novel biomarkers and develop effective therapeutic strategies is paramount. This study used a comprehensive machine learning approach to identify key predictive genes for CD, including S100A8, IGFBP5, CTSK, and S100P.
View Article and Find Full Text PDFIntegrating population-level and cell-based signatures for drug repositioning.
Bioinformatics
September 2025
The Second Affiliated Hospital and School of Public Health, Zhejiang University School of Medicine, Hangzhou, China.
Motivation: Drug repositioning presents a streamlined and cost-efficient way to expand the range of therapeutic possibilities. Drugs with human genetic evidence are more likely to advance successfully through clinical trials towards FDA approval. Single gene-based drug repositioning methods have been implemented, but approaches leveraging a broad spectrum of molecular signatures remain underexplored.
View Article and Find Full Text PDFNetwork Medicine-Based Repurposing of Mesalazine for Atherosclerosis Treatment.
J Cardiovasc Transl Res
September 2025
School of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai, 519000, China.
Atherosclerosis remains a leading cause of cardiovascular disease and mortality worldwide, despite advancements in statin therapies. Here, we aimed to identify potential anti-atherosclerosis drugs by an integrated approach combining network medicine-based prediction with empirical validation. Among the top drugs predicted by the preferred algorithm, mesalazine─a drug traditionally used to treat inflammatory bowel disease, was selected for in vivo validation in ApoE mouse model of atherosclerosis.
View Article and Find Full Text PDF